Çocuklarda Kalp ve Kalp/Akciğer Transplantasyonu

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-1032.

Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol. 2012 Dec;33(8):1295-300. doi: 10.1007/s00246-012-0306-8. Epub 2012 Apr 5. PMID: 22476605.

Amdani S, Conway J, George K, Martinez HR, Asante-Korang A, Goldberg CS; American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Surgery and Anesthesia; and Council on Cardiovascular and Stroke Nursing. Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation. 2024 Jul 9;150(2):e33-e50. doi: 10.1161/CIR.0000000000001245. Epub 2024 May 29. PMID: 38808502.

Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM; American Heart Association Young Hearts Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts). Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. Circulation. 2023 Jul 11;148(2):174-195. doi: 10.1161/CIR.0000000000001151. Epub 2023 Jun 8. Erratum in: Circulation. 2023 Jul 11;148(2):e3. doi: 10.1161/CIR.0000000000001170. PMID: 37288568.

Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021 May 14;128(10):1487-1513. doi: 10.1161/CIRCRESAHA.121.318241. Epub 2021 May 13. PMID: 33983836; PMCID: PMC8136750.

Carrel A. Suture of blood-vessels and transplantation of organs. In: Nobel Lectures, Physiology or Medicine 1901-1921. Amsterdam: Elsevier Publishing Company, 1967. http:// nobelprize.org/medicine/laureates/1912/carrel-lecture.html. Accessed July 29, 2005.

Anonymous. The Nobel Prize in Physiology or Medicine 1912. http://nobelprize.org/medicine/laureates/1912. Accessed July 29, 2005.

Shumway NE. The experimental basis for heart transplantation. Bull Am Coll Surg. June 1981; 66:6-10.

Konstantinov IE. A mystery of Vladimir P. Demikhov: the 50th anniversary of the first intrathoracic transplantation. Ann Thorac Surg. 1998 Apr;65(4):1171-7. doi: 10.1016/s0003-4975(97)01308-8. PMID: 9564962.

Hardy JD. The world of surgery, 1945-1985: memoirs of one participant. University of Pennsylvania Press, 2017.

Lower RR, Shumway NE. Studies on orthotopic homotransplantation of the canine heart. Surg Forum. 1960;11:18–19.

Lower RR, Stofer RC, Hurley EJ, et al. Successful homotransplantations of the canine heart after anoxic preservation for seven hours.Am J Surg. 1962;104:302–306.

Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41:1271–1274.

Griepp RB. A decade of human heart transplantation. Transplant Proc 1979;11:285-92.

Caves PK, Stinson EB, Graham AF, et al. Percutaneous transvenous endomyocardial biopsy. JAMA.1973;225:288–291.

Caves PK, Stinson EB, Billingham ME, Shumway NE. Serial transvenous biopsy of the transplanted human heart.Improved management of acute rejection episodes. Lancet. 1974;1:821–826.

Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporin-A in cardiac allografting: a preliminary experience. Transplant Proc. 1983;3:172.

Kobashigawa JA. Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine.Transplant Proc. 1998;30:1095–1097.

Dipchand AI, Benson L, McCrindle BW, Coles J, West L. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant. 2001;5:112–118.

Canter CE,Moorhead S,Saffitz JE,Huddelston CB,Spray TL. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant. 1994;13(1Pt 1):74–80.

Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.N Engl J Med. 2000;342:613–619.

Kantrowitz A, Haller JD, Joos H, Cerruti MM, Carstensen HE. Transplantation of the heart in an infant and an adult. Am J Cardiol. 1968;22:782-90.

Cooley DA, Frazier OH, Van Buren CT, Bricker JT, Radovancevic B. Cardiac transplantation in an 8-month-old female infant with subendocardial fibroelastosis. JAMA. 1986;256:1326-9.

Bailey LL, Nehlsen-Cannarella SL, Doroshow RW, et al. Cardiac allotransplantation in newborns as therapy for hypoplastic left heart syndrome. N Engl J Med. 1986;315:949–951.

Vazquez Alvarez MDC, Cantor R, Koehl D, Nandi D, Kemna MS, Urschel S, et al. The evolution of pediatric heart retransplantation over three decades: An analysis from the PHTS. J Heart Lung Transplant. 2022 Jun;41(6):791-801. doi: 10.1016/j.healun.2022.02.018. Epub 2022 Mar 14. PMID: 35400589.

Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335. doi: 10.21037/cdt-20-358. PMID: 33708503; PMCID: PMC7944205.

Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Feb;21(2):137-155. doi: 10.1002/ejhf.1369. Epub 2019 Jan 1. PMID: 30600580.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. PMID: 25176015.

Shaddy R, Burch M, Kantor PF, Solar-Yohay S, Garito T, Zhang S; PANORAMA-HF Investigators. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation. 2024 Nov 26;150(22):1756-1766. doi: 10.1161/CIRCULATIONAHA.123.066605. Epub 2024 Sep 25. PMID: 39319469; PMCID: PMC11593999.

Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov;33(22):2782-95. doi: 10.1093/eurheartj/ehs257. Epub 2012 Aug 31. PMID: 22942339.

Garcia AM, Beatty JT, Nakano SJ. Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations. Am J Physiol Heart Circ Physiol. 2020 Apr 1;318(4):H947-H965. doi: 10.1152/ajpheart.00518.2019. Epub 2020 Feb 28. PMID: 32108525; PMCID: PMC7191494.

Kumar SS, Gopalakrishnan A, Krishnamoorthy KM, Naik S, Sivadasanpillai H. The efficacy and safety of dapagliflozin in pediatric heart failure. Int J Cardiol. 2025 Sep 15;435:133384. doi: 10.1016/j.ijcard.2025.133384. Epub 2025 May 22. PMID: 40412628.

Brown DW, Mangeot C, Anderson JB, Peterson LE, King EC, Lihn SL; National Pediatric Cardiology Quality Improvement Collaborative. Digoxin Use Is Associated With Reduced Interstage Mortality in Patients With No History of Arrhythmia After Stage I Palliation for Single Ventricle Heart Disease. J Am Heart Assoc. 2016 Jan 11;5(1):e002376. doi: 10.1161/JAHA.115.002376. PMID: 26755552; PMCID: PMC4859359.

Luxford JC, Casey CE, Roberts PA, Irving CA. Iron deficiency and anemia in pediatric dilated cardiomyopathy are associated with clinical, biochemical, and hematological markers of severe disease and adverse outcomes. J Heart Lung Transplant. 2024 Mar;43(3):379-386. doi: 10.1016/j.healun.2023.11.014. Epub 2023 Nov 25. PMID: 38012978.

Shaddy RE, George AT, Jaecklin T, et al. Systematic Literature Review on the Incidence and Prevalence of Heart Failure in Children and Adolescents. Pediatr Cardiol 2018;39:415-36.

Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. J Heart Lung Transplant 2014;33:888-909.

Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.

Robel-Tillig E, Knupfer M, Pulzer F, et al. Cardiovascular impact of dobutamine in neonates with myocardial dysfunction. Early Hum Dev 2007;83:307-12.

Lipshultz SE, Sleeper LA, Towbin JA, et al: The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348:1647, 2003.

Tsirka AE, Trinkaus K, Chen SC, et al: Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol 44:391, 2004.

Sugiyama H, Hoshiai M, Naitoh A, et al: Outcome of non-transplant surgical strategy for end-stage dilated cardiomyopathy in young children. Circ J 73:1045, 2009.

Nield LE, McCrindle BW, Bohn DJ, et al. Outcomes for children with cardiomyopathy awaiting transplantation. Cardiol Young 10:358, 2000.

Fiser WP, Yetman AT, Gunselman RJ, et al: Pediatric arteriovenous extracorporeal membrane oxygenation (ECMO) as a bridge to cardiac transplantation. J Heart Lung Transplant 22:770, 2003.

Kirshbom PM, Bridges ND, Myung RJ, et al: Use of extracorporeal membrane oxygenation in pediatric thoracic organ transplantation. J Thorac Cardiovasc Surg 123:130, 2002.

Pollock JC, Charlton MC, Williams WG, et al: Intraaortic balloon pumping in children. Ann Thorac Surg 29:522, 1980.

Karl TR, Sano S, Horton S, et al: Centrifugal pump left heart assist in pediatric cardiac operations. Indication, technique, and results. J Thorac Cardiovasc Surg 102:624, 1991.

Hetzer R, Loebe M, Potapov EV, et al: Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Ann Thorac Surg 66:1498, 1998.

Baldwin JT, Borovetz HS, Duncan BW, et al: The National Heart, Lung, and Blood Institute Pediatric Circulatory Support Program. Circulation 113:147, 2006.

Arabía FA, Tsau PH, Smith RG, et al: Pediatric bridge to heart transplantation: application of the Berlin Heart, Medos and Thoratec ventricular assist devices. J Heart Lung Transplant 25:16, 2006.

Duncan BW, Bohn DJ, Atz AM, et al: Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg 122:440, 2001.

del Nido PJ, Armitage JM, Fricker FJ, et al: Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation. Circulation 90:66, 1994.

Bastardi HJ, Naftel DC, Webber SA, et al: Ventricular assist devices as a bridge to heart transplantation in children. J Cardiovasc Nur 23:25, 2008.

Yarlagadda VV, Maeda K, Zhang Y, et al. Temporary Circulatory Support in U.S. Children Awaiting HTx. J Am Coll Cardiol. 2017; 70: 2250–2260.

Kocabas S, Askar FZ, Yagdi T, Engin C, Ozbaran M. Anesthesia for ventricular assist device placement in pediatric patients: experience from a single center. Transplant Proc. 2013 Apr;45(3):1009-12. doi: 10.1016/j.transproceed.2013.02.068. PMID: 23622610.

Warnecke H, Berdjis F, Hennig E, et al: Mechanical left ventricular support as a bridge to cardiac transplantation in childhood. Eur J Cardiothorac Surg 5:330, 1991.

Rossano JW, Singh TP, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric heart transplantation report – 2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019;38:1028–1041.

Rossano JW, Lorts A, VanderPluym CJ, Jeewa A, Guleserian KJ, Bleiweis MS, et al. Outcomes of pediatric patients supported with continuous-flow ventricular assist devices: A report from the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS). J Heart Lung Transplant 2016;35:585-90.

Almond CS, Morales DL, Blackstone EH, et al. Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation. 2013; 127: 1702–1711.

Soslow JH, Patel AR, Abraham JR, et al. Neurological outcomes in pediatric LVAD patients. Pediatr Neurol. 2020; 107: 54–60.

Doğan E, Ulger Tutar Z, Tuncer ON, Levent RE, Engin Ç, Yağdı T, et al. Outcomes of HeartMate 3 in pediatric patients with end-stage heart failure: a single-center preliminary experience from Turkey. Front Cardiovasc Med. 2024 Oct 14;11:1472663. doi: 10.3389/fcvm.2024.1472663. PMID: 39469126; PMCID: PMC11513339.

Fraser CD Jr, Jaquiss RD, Rosenthal DN, et al. Prospective trial of pediatric VAD. N Engl J Med. 2012; 367: 532–541.

Miller JR, Lancaster TS, Eghtesady P. Current approaches to device implantation in pediatric and congenital heart disease patients. Expert Rev Cardiovasc Ther. 2015; 13: 417-427.

Ayik F, Oguz E, Engin C, Yagdi T, Ulger Z, Atay Y, et al. Surgical therapy of end-stage heart failure in pediatric patients. Transplant Proc. 2011 Apr;43(3):935-7.

Kirklin JK, Naftel DC. Mechanical circulatory support: registering a therapy in evolution. Circ Heart Fail 2008;1:200-5.

Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012 Oct 8;172(18):1386-94. doi: 10.1001/archinternmed.2012.3310. PMID: 22945249.

Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. J Pediatr. 2014 Aug;165(2):228-33. doi: 10.1016/j.jpeds.2014.04.055. Epub 2014 Jun 11. PMID: 24928699.

Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003 Apr 24;348(17):1647-55. doi: 10.1056/NEJMoa021715. PMID: 12711739.

Lee TM, Hsu DT, Kantor P, et al. Pediatric cardiomyopathies.Circ Res. 2017;121:855–873.

Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin. 2010 Oct;6(4):401-13, vii. doi: 10.1016/j.hfc.2010.05.002. PMID: 20869642; PMCID: PMC2946942.

Andrews RE, Fenton MJ, Ridout DA, Burch M; British Congenital Cardiac Association. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland. Circulation. 2008 Jan 1;117(1):79-84. doi: 10.1161/CIRCULATIONAHA.106.671735. Epub 2007 Dec 17. PMID: 18086928.

Kantor PF, Abraham JR, Dipchand AI, Benson LN, Redington AN. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol. 2010;55:1377–1384.

Connuck DM, Sleeper LA, Colan SD, et al.; Pediatric Cardiomyopathy Registry Study Group. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008;155:998–1005.

McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690–695.

Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007 Feb 13;115(6):773-81. doi: 10.1161/CIRCULATIONAHA.106.621185. Epub 2007 Jan 29. PMID: 17261650.

Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ; Pediatric Cardiomyopathy Registry Investigators. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation. 2012 Sep 4;126(10):1237-44. doi: 10.1161/CIRCULATIONAHA.112.104638. Epub 2012 Jul 27. PMID: 22843787.

Russo LM, Webber SA. Idiopathic restrictive cardiomyopathy inchildren. Heart 2005;91:1199–1202.

Gerecke BJ, Engberding R. Noncompaction Cardiomyopathy-History and Current Knowledge for Clinical Practice. J Clin Med. 2021 Jun 1;10(11):2457. doi: 10.3390/jcm10112457. PMID: 34206037; PMCID: PMC8199228.

Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816.

Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 Nov;16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007. Epub 2019 May 9. PMID: 31078652.

Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014 Jan;11(1):158-62. doi: 10.1016/j.hrthm.2013.10.026. Epub 2013 Oct 10. PMID: 24121001.

Crosson JE, Nies M. Brugada syndrome in children. Expert Rev Cardiovasc Ther. 2015 Feb;13(2):173-81. doi: 10.1586/14779072.2015.999765. Epub 2015 Jan 13. PMID: 25583159.

Xiong Q, Cao Q, Zhou Q, Xie J, Shen Y, Wan R, et al. Arrhythmogenic cardiomyopathy in a patient with a rare loss-of-function KCNQ1 mutation. J Am Heart Assoc. 2015 Jan 23;4(1):e001526. doi: 10.1161/JAHA.114.001526. PMID: 25616976; PMCID: PMC4330077.

Cheung CC, Healey JS, Hamilton R, Spears D, Gollob MH, Mellor G, et al. Phospholamban cardiomyopathy: a Canadian perspective on a unique population. Neth Heart J. 2019 Apr;27(4):208-213. doi: 10.1007/s12471-019-1247-0. PMID: 30806910; PMCID: PMC6439019.

Dipchand A, Kirk R, Mahle W, Tresler M, et al. Ten years of pediatric heart transplantation: a report from the pediatric heart transplant study. Pediatr Transplant. 2013;17:99-111.

Hsu DT, Naftel DC, Webber SA, Morrow WR, Canter CE, Chinnock RE, et al. Lessons learned from the pediatric heart transplant study. Congenit Heart Dis. 2006 May;1(3):54-62. doi: 10.1111/j.1747-0803.2006.00011.x. PMID: 18377548.

Morrow WR, Frazier E, Naftel DC. Survival after listing for cardiac transplantation in children. Prog Pediatr Cardiol. 2001;11:99–105.

Norwood WI, Lang P, Hansen D. Physiologic repair of aortic atresia-hypoplastic left heart syndrome. N Engl J Med. 1983;308:23-26.

Ohye RG, Sleeper LA, Mahony L, et al.; Pediatric Heart Network Investigators. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010;362:1980–1992.

Dipchand AI, Webber SA. Pediatric heart transplantation: Looking forward after five decades of learning. Pediatr Transplant. 2024 Feb;28(1):e14675. doi: 10.1111/petr.14675. Epub 2023 Dec 8. PMID: 38062996.

Dipchand AI. Current state of pediatric cardiac transplantation. Ann Cardiothorac Surg. 2018;7:31-35.

Siehr SL, Maeda K, Connolly AA, etal. Mitral stenosis and Aortic atresia — a risk factor for mortality after the modified Norwood operation in hypoplastic left heart syndrome. Ann Thorac Surg. 2016;101:162–167.

Ekman-Joelsson BM, Berggren H, Boll AB, Sixt R, Sunnegårdh J. Abnormalities in myocardial perfusion after surgical correction of pulmonary atresia with intact ventricular septum. Cardiol Young. 2008;18:89–95.

Larsen RL, Eguchi JH, Mulla NF, et al. Usefulness of cardiac transplantation in children with visceral heterotaxy (asplenic and polysplenic syndromes and single right-sided spleen with levocardia) and comparison of results with cardiac transplantation in children with dilated cardiomyopathy. Am J Cardiol. 2002;89:1275–1279.

Nollert G, Fischlein T, Bouterwek S, et al. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol. 1997;30:1374–1383.

Graham TP, Bernard YD, Mellen BG, etal. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255–261.

Backer CL, Russell HM, Pahl E, et al. Heart transplantation for the failing Fontan. Ann Thorac Surg. 2013;96:1413–1419.

Mavroudis C, Deal BJ, Backer CL, et al. J.MaxwellChamberlain Memorial Paper for congenital heart surgery.111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg. 2007;84:1457–1466.

Deal BJ, Costello JM, Webster G, et al. Intermediate-term outcome of 140 consecutive Fontan conversions with arrhythmia operations. Ann Thorac Surg. 2016;101:717–724.

Ridderbos FJ, Wolff D, Timmer A, et al. Adverse pulmonary vascular remodeling in the Fontan circulation. J Heart Lung Transplant. 2015;34:404 413.

Greenway SC, Crossland DS, Hudson M, et al. Fontan- associated liver disease: implications for heart transplantation. J Heart Lung Transplant. 2016;35:26–33.

Webber SA, Fricker FJ, Michael M, et al. Orthotopic heart transplantation in children with congenital heart disease. Ann Thorac Surg 1994;58(6):1664-1669.

Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol 2009;54(2):160-165.

Rychik J, Atz AM, Celermajer DS, et al. Evaluation and manage- ment of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140(6):e234-e284.

Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, Dipchand AI. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2014;33:241–51.

Bock MJ, Nguyen K, Malerba S, Harrison K, Bagiella E, Gelb BD, et al. Pediatric cardiac retransplantation: waitlist mortality stratified by age and era. J Heart Lung Transplant. 2015;34:530–7.

Mahle WT, Vincent RN, Kanter KR. Cardiac retransplantation in childhood: analysis of data from the United Network for Organ Sharing. J Thorac Cardiovasc Surg. 2005;130:542–6.

Mongé MC, Kulat BT, Eltayeb O, et al. Successful bridge-to-transplant of functionally univentricular patients with a modified continuous-flow ventricular assist device. Artif Organs. 2017;41:25–31.

Dipchand AI, Rossano JW, Edwards LB, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society of Heart and Lung Transplantation: eighteenth official pediatric heart transplantation report—2015: Focus theme: early graft failure. J Heart Lung Transplant. 2015;34:1233–1243.

Uriel N, Nahumi H, Colombo PC, et al. Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care? J Heart Lung Transplant. 2014;33:924–930.

Ozturk P, Engin AY, Nalbantgil S, Oguz E, Ayik F, Engin C, et al. Comparison of continuous-flow and pulsatile-flow blood pumps on reducing pulmonary artery pressure in patients with fixed pulmonary hypertension. Artif Organs. 2013 Sep;37(9):763-7. doi: 10.1111/aor.12164. Epub 2013 Sep 11. PMID: 24033601.

Goldfarb SB, Benden C, Edwards LB, et al.The Registry of the International Society for Heart and Lung Transplantation: eighteenth official pediatric lung and heart-lung transplantation report—2015; Focus them: early graft failure. J Heart Lung Transplant. 2015;34:1255–1263.

Schumacher KR, Almond C, Singh TP, et al.; PHTS Study Group Investigators. Predicting graft loss by 1 year in pediatric heart transplantation candidates: an analysis of the Pediatric Heart Transplant Study database. Circulation. 2015;131:890–898.

Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant. 2007;26:876–882.

Razzouk AJ, Johnston JK, Larsen RL, et al. Effect of oversizing cardiac allografts on survival in pediatric patients with congenital heart disease. J Heart Lung Transplant. 2005;24:195–199.

Chin C, Miller J, Robbins R, Reitz B, Bernstein D. The use of advanced-age donor hearts adversely affects survival in pediatric heart transplantation. Pediatr Transplant. 1999;3:309–314.

Cooper DK, Novitzky D, Wicomb WN. The pathophysiological effects of brain death on potential donor organs, withparticularreferencetotheheart. Ann R Coll Surg Engl. 1989;71:261–266.

Copeland H, Knezevic I, Baran DA, Rao V, Pham M, Gustafsson F, et al. Donor heart selection: Evidence-based guidelines for providers. J Heart Lung Transplant. 2023 Jan;42(1):7-29. doi: 10.1016/j.healun.2022.08.030. Epub 2022 Sep 20. PMID: 36357275; PMCID: PMC10284152.

Bailey LL, Razzouk AJ, Hasaniya NW, Chinnock RE. Pediatric transplantation using hearts refused on the basis of donor quality. Ann Thorac Surg. 2009;87:1902–1909.

West LJ. ABO-incompatible hearts for infant transplantation. Curr Opin Organ Transplant. 2011;16:548–554.

Buckberg GD. Update on current tecniques of miyocardial protection. Ann Thorac Surg 1995;60:805-14.

Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987;43:852-4.

Macdonald P, Dhital K. Heart transplantation from donation-after-circulatory-death (DCD) donors: Back to the future—Evolving trends in heart transplantation from DCD donors. The Journal of Heart and Lung Transplantation . 2019;38:599–600.

Pettit SJ, Petrie MC. Transplantation of Hearts Donated after Circulatory-Determined Death. Circulation: Heart Failure . 2019;12:e005991.

Croome KP, Taner CB. Warm Ischemia Time. Donation after Circulatory Death (DCD) Liver Transplantation . 2020;85:61–71.

Anguela-Calvet L, Moreno-Gonzalez G, Sbraga F, Gonzalez-Costello J, Tsui S, Oliver-Juan E. Heart Donation from Donors after Controlled Circulatory Death. Transplantation . 2021;105:1482–1491.

Noterdaeme T, Detry O, Hans M, Nellessen E, Ledoux D, Joris J, et al. What is the potential increase in the heart graft pool by cardiac donation after circulatory death. Transplant International . 2013;26:61–66.

Messer S, Page A, Rushton S, Berman M, Tsui S, Catarino P, et al. The potential of heart transplantation from donation after circulatory death donors within the United Kingdom. The Journal of Heart and Lung Transplantation . 2019;38:872–874.

Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, et al. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. American Journal of Transplantation . 2019;19:1745–1758.

Antoine C, Savoye E, Gaudez F, Cheisson G, Badet L, Videcoq M, et al. Kidney Transplant from Uncontrolled Donation after Circulatory Death: Contribution of Normothermic Regional Perfusion. Transplantation . 2020;104:130–136.

Smith DE, Kon ZN, Carillo JA, Chen S, Gidea CG, Piper GL, et al. Early experience with donation after circulatory death heart transplantation using normothermic regional perfusion in the United States. The Journal of Thoracic and Cardiovascular Surgery . 2022;164:557–568.

Messer S, Page A, Axell R, Berman M, Hernández-Sánchez J, Colah S, et al. Outcome after heart transplantation from donation after circulatory-determined death donors. The Journal of Heart and Lung Transplantation . 2017;36:1311–1318.

Messer S, Page A, Colah S, Axell R, Parizkova B, Tsui S, et al. Human heart transplantation from donation after circulatory-determined death donors using normothermic regional perfusion and cold storage. The Journal of Heart and Lung Transplantation . 2018;37:865–869.

Hoffman JRH, McMaster WG, Rali AS, Rahaman Z, Balsara K, Absi T, et al. Early us experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion. The Journal of Heart and Lung Transplantation . 2021;40:1408–1418.

Beaupré RA, Morgan JA. Donation after Cardiac Death: a Necessary Expansion for Heart Transplantation. Seminars in Thoracic and Cardiovascular Surgery . 2019;31:721–725.

Page AA, Messer S, Tsui SS, Large SR. Early Results Using Donation after Circulatory Death (DCD) Donor Hearts. Current Transplantation Reports . 2016;3:199–206.

Hameed AM, Hawthorne WJ, Pleass HC. Advances in organ preservation for transplantation. ANZ Journal of Surgery . 2017;87:976–980.

Sponga S, Benedetti G, de Manna ND, Ferrara V, Vendramin I, Lechiancole A, et al. Heart transplant outcomes in patients with mechanical circulatory support: cold storage versus normothermic perfusion organ preservation. Interactive CardioVascular and Thoracic Surgery . 2021;32:476–482.

Pahuja M, Case BC, Molina EJ, Waksman R. Overview of the FDA’s Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart – portable extracorporeal heart perfusion and monitoring system. American Heart Journal . 2022;247:90–99.

Monteagudo Vela M, García Sáez D, Simon AR. Current approaches in retrieval and heart preservation. Annals of Cardiothoracic Surgery . 2018;7:67–74.

Rojas SV, Avsar M, Ius F, Schibilsky D, Kaufeld T, Benk C, et al. Ex-vivo Preservation with the Organ Care System in High Risk Heart Transplantation. Life . 2022;12:247.

Beuth J, Falter F, Pinto Ribeiro RV, Badiwala M, Meineri M. New Strategies to Expand and Optimize Heart Donor Pool. Anesthesia & Analgesia . 2019;128:406–413.

García Sáez D, Zych B, Sabashnikov A, Bowles CT, De Robertis F, Mohite PN, et al. Evaluation of the Organ Care System in Heart Transplantation with an Adverse Donor/Recipient Profile. The Annals of Thoracic Surgery . 2014;98:2099–2106.

Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. The Lancet . 2015;385:2577–2584.

Kaliyev R, Lesbekov T, Bekbossynov S, Nurmykhametova Z, Bekbossynova M, Novikova S, et al. Heart transplantation of patients with ventricular assist devices: impact of normothermic ex-vivo preservation using organ care system compared with cold storage. Journal of Cardiothoracic Surgery . 2020;15:323.

Schroder JN, Patel CB, DeVore AD, Bryner BS, Casalinova S, Shah A, et al. Transplantation Outcomes with Donor Hearts after Circulatory Death. N Engl J Med. 2023 Jun 8;388(23):2121-2131.

Fleck TPK, Ayala R, Kroll J, Siepe M, Schibilsky D, Benk C, et al. Ex vivo Allograft Perfusion for Complex Pediatric Heart Transplant Recipients. The Annals of Thoracic Surgery . 2021;112:1275–1280.

Neyrinck A, Van Raemdonck D, Monbaliu D. Donation after circulatory death. Current Opinion in Anaesthesiology . 2013;26:382–390.

Backer CL, Idriss FS, Zales VR, Mavroudis C. Cardiac transplantation for hypoplastic left heart syndrome: a modified technique. Ann Thorac Surg. 1990;50:894–898.

Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–475.

Boucek RJ Jr, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung Transplant. 1999;18:460–469.

Caves PK, Billingham ME, Stinson EB, Shumway NE. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet 1974;821-26

Reitz BA, Bieber CP, Raney AA, et al. Orthotopic heart and combined heart-lung transplantation with cyclosporine A immunosuppression. Transplant Proc 1981;13:393-6.

Trehan S, Taylor DO, Renlund DG. New pharmacologic immunsuppressive agents. In: Cooper DKC, Miller LW, Patterson GA, editors. The transplantation and replacement of thoracic organs: the Present Status of Biological and Mechanical Replacement of the Heart and Lungs. Lancaster: Kluwer Academic Publishers; 1996:35-60.

Perico N, Remuzzi G. Prevention of transplant rejection. Current treatment guidelines and future developments. Drugs 1997;54:533-70..

Engin Ç, Yağdı T, Nalbantgil S, Zoghi M, Özbaran M, “İmmunsupressif tedavi”, Türkiye Klinikleri Cerrahi Tıp Bilimleri 2006;2, 53-61.

Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on cardiovascular disease in the young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;115(5), 658–676.

Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric hearttransplantation. Transplantation 2003;75(3), 354–358.

Irving CA, Webber SA. Immunosuppression therapy for pediatric heart transplantation. Curr. Treat. Options Cardiovasc. Med. 2010;12(5),489–502.

Butts RJ, Dipchand AI, Sutcliffe D, et al. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric hearttransplant recipients: an analysis of the International Society for Heart and Lung Transplantation database. Pediatr. Transplant. 2018;22(4),e13190.

Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, et al. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. J Heart Lung Transplant. 2020 Oct;39(10):1050-1069. doi: 10.1016/j.healun.2020.06.024. Epub 2020 Jul 10. PMID: 32883559.

Simmonds J, Dewar C, Dawkins H, Burch M, Fenton M. Tacrolimus in pediatric heart transplantation: ameliorated side effects in thesteroid-free, statin era. Clin. Transplant. 2009;23(3), 415–419.

Robinson BV, Boyle GJ, Miller SA et al. Optimal dosing of intravenous tacrolimus following pediatric heart transplantation. J. HeartLung Transplant. 1999;18(8), 786–791.

D’addese L, Joong A, Burch M, Pahl E. Pediatric heart transplantation in the current era. Curr. Opin. Pediatr. 2019;31(5), 583–591.

Ye F, Ying-Bin X, Yu-Guo W, Hetzer R. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009; 28: 58–66.

Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetilversus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. 2005;24(5), 517–525.

Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and youngadult cardiac transplant patients: does the MPA level matter? Am. J. Transplant. 2004;4(9), 1495–1500.

Gustafsson F, Andreassen AK, Andersson B et al. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo hearttransplant recipients: long-term follow-up from the randomized SCHEDULE study. Transplantation 2020;104(1), 154–164.

Raichlin E, Bae JH, Khalpey Z et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograftvasculopathy after cardiac transplantation. Circulation 2007;116(23), 2726–2733.

Asante-Korang A, Carapellucci J, Krasnopero D, Doyle A, Brown B, Amankwah E. Conversion from calcineurin inhibitors to mTORinhibitors as primary immunosuppressive drugs in pediatric heart transplantation. Clin. Transplant.2017;31(10).

Rosenthal LM, Nordmeyer J, Kramer P et al. Long-term experience using CNI-free immunosuppression in selected paediatric hearttransplant recipients. Pediatr. Transplant. 2021;25(8), e14111.

Smith RR, Wray J, Khaghani A, Yacoub M. Ten year survival after paediatric heart transplantation: a single centre experience. Eur. J.Cardiothorac. Surg. 2005;27(5), 790–794.

Singh TP, Faber C, Blume ED et al. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol inpediatric heart transplant recipients. J. Heart Lung Transplant. 2010;29(5), 517–522.

Kaposztas Z, Podder H, Mauiyyedi S et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin. Transplant. 2009;23(1),63–73.

Morrow WR, Frazier EA, Mahle WT et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal ofantibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012;93(3), 319–324.

Patel JK, Kobashigawa JA. Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection? Curr Opin Cardiol. 2006;21:127–31.

From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc. 2011;86:1095–102.

Aggarwal S, Blake J, Sehgal S. Right ventricular dysfunction as an echocardiographic measure of acute rejection following heart transplantation in children. Pediatr Cardiol. 2017;38:442–7.

Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valentine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the invasive monitoring attenuation through gene expression (IMAGE) trial. J Heart Lung Transplant. 2007;26:808–14.

Pascual-Figal DA, Garrido IP, Blanco R, Minguela A, Lax A, Ordoñez-Llanos J, et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg. 2011;92:2118–24.

Dyer AK, Barnes AP, Fixler DE, Shah TK, Sutcliffe DL, Hashim I, et al. Use of a highly sensitive assay for cardiac troponin T and N-terminal probrain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients. Am Heart J. 2012;163:595–600.

Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013;32:120–8.

Daly KP. Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine. Cardiol Young. 2015;25 Suppl 2(Suppl 2):117–23.

Martinez-Dolz L, Almenar L, Reganon E, Vila V, Sanchez-Soriano R, Martinez-Sales V, et al. What is the best biomarker for diagnosis of rejection in the heart transplantation? Clin Tranplant. 2009;23:672–80.

Mathews LR, Lott JM, Isse K, Lesniak A, Landsittel D, Demetris AJ, et al. Elevated ST2 distinguishes incidences of pediatric heart and small bowel transplant rejection. Am J Transplant. 2016;16:938–50.

Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150–60.

VanBuskirk AM, Pidwell DJ, Adams PW, Orosz CG. Transplantation immunology. JAMA. 1997;278:1993–9.

Agbor-Enoh S, Tunc I, Vlaminck ID, Fideli U, Davis A, Cuttin K, et al. Applying rigor and reproducibility standards to assay donor-drived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. J Heart Lung Transplant. 2017;36:1004–12.

Khush KK, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, et al. Noninvasive detection of graft injury after heart transplant using donor-drived cell-free DNA: a prospective multicenter study. Am J Transplant. 2019;19:2889–99.

Phelps CM, Tissort C, Buckvold S, Gralla J, Ivy DD, Pietra BA, et al. Outcome of acute graft rejection associated with hemodynamic compromise in pediatric heart transplant recipients. Pediatr Cardiol. 2011;32:1–7.

Costanza MR. Special feature: The international society of heart and lung transplantation: Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.

Stoica S, Math FC, Pauriah M, Taylor CJ, Sharples LD, Wallwork J, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006;25:420–5.

Pollock-Barziv SM, Den Hollander N, Ngan BY et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients:evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007;116(Suppl. 11), I172–178.

Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Rainsmoen NL, et al. Acute antibody mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25:153–9.

Rossano JW, Dipchand AI, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: nineteenth Pediatric Heart Transplantation Report—2016: Focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1185–1195.

Morales DLS, Adachi I, Peng DM,et al.; Pedimacs Investigators. Fourth Annual Pediatric Interagency Registry for Mechanical Circulation Support (Pedimacs) Report. Ann Thorac Surg. 2020;110:1819–1831.

Ozbaran M, Yagdi T, Engin C, Ulger Z, Ozbaran B, Kose S, et al. New era of pediatric ventricular assist devices: let us go to school. Pediatr Transplant. 2015 Feb;19(1):82-6. doi: 10.1111/petr.12399. Epub 2014 Nov 22. PMID: 25418779.

Jacobs JP, Jacobs ML, Mavroudis C, et al. Executive summary: The Society of Thoracic Surgeons Congenital Heart Surgery Database – Twenty-seventh Harvest – (July 1, 2013 – June 30, 2017). The Society of Thoracic Surgeons (STS) and Duke Clinical Research Institute (DCRI), Duke University Medical Center, Durham, North Carolina, United States, Fall 2017 Harvest.

Dipchand AI, Kirk R, Mahle WT, et al. Ten yr of pediatric heart transplantation: a report from the Pediatric Heart Transplant Study. Pediatr Transplant. 2013;17:99–111.

Kobayashi D, Du W, L’Ecuyer TJ. Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients. Pediatr Transplant. 2013;17:436–440.

Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant. 2005;24:645–651.

Rossano JW, Cherikh WS, Chambers DC, et al. The Registry of the International Society for Heart and Lung Transplantation : Twentieth Pediatric Heart Transplantation Report — 2017 ; Focus Theme : Allograft ischemic time. J Heart Lung Transplant. 2017;36:1060–1069.

Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005;2:63–66.

Greenway SC, Butts R, Naftel DC, et al. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents. J Heart Lung Transplant. 2016;35:457–465.

Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–858.

Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700.

Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation. 2011;92:235–243.

Kindel SJ, Pahl E. Current therapies for cardiac allograft vasculopathy in children. Congenit Heart Dis. 2012;7:324–335.

Wright EJ, Fiser WP, Edens RE, et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant. 2007;26:1163–1169.

Feingold B, Zheng J, Law YM, et al. Risk factors for late renal dysfunction after pediatric heart transplantation: a multi-institutional study. Pediatr Transplant. 2011;15:699–705.

Rostad CA, Wehrheim K, Kirklin JK, et al. Bacterial infections after pediatric heart transplantation: epidemiology, risk factors and outcomes. J Heart Lung Transplant. 2017;36:996–1003.

Mahle WT, Fourshee MT, Naftel DM, et al. Does cytomegalovirus serology impact outcome after pediatric heart transplantation? J Heart Lung Transplant. 2009;28:1299–1305.

Dipchand AI, Kirk R, Naftel DC, et al. Ventricular assist device support as a bridge to transplantation in pediatric patients. J Am Coll Cardiol. 2018;72:402–415.

Ng B, Dipchand A, Naftel D, et al. Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. Pediatr Transplant. 2011;15:844–848.

Hayes EA, Nandi D, Lewis M, Ouellette CP, Wright LK. Pneumocystis jiroveci Pneumonia Infections in Pediatric Solid Organ Transplant Recipients. Pediatr Transplant. 2025 Jun;29(4):e70107.

Hayes EA, Koehl D, Cantor R, Fisher LA, Azeka E, Mokshagundam D, et al. Long-Term Survival in Children Following Heart Transplantation. Pediatr Transplant. 2025 Mar;29(2):e70042.

Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367:233–239.

Spahr JE, West SC. Heart-lung transplantation: pediatric indications and outcomes. J Thorac Dis. 2014 Aug;6(8):1129-37. doi: 10.3978/j.issn.2072-1439.2014.07.05. PMID: 25132980; PMCID: PMC4133540.

Beaty CA, George TJ, Kilic A, Conte JV, Shah AS. Pre‐transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant. 2013; 32:202–211.

Kern RM, Seethamraju H, Blanc PD, et al. The feasibility of lung transplantation in HIV‐seropositive patients. Ann Am Thorac Soc. 2014; 11:882–889.

Faro A, Shepherd R, Huddleston CB, et al. Lower incidence of bronchiolitis obliterans in pediatric liver‐lung transplant recipients with cystic fibrosis. Transplantation. 2007; 83:1435–1439.

De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single‐center experience. J Heart Lung Transplant. 2010; 29:1395–1404.

Charles B. Huddleston, Andrew C. Fiore. (2023) Lung and Heart–Lung Transplantation In: Constantine Mavroudis, Carl L. Backer, Pediatric Cardiac Surgery, Fifth Edition, John Wiley & Sons, Ltd, p:941 Print ISBN:9781119282310 |Online ISBN:9781119282327.

Bhorade S, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc. 2009; 6:47–53.

Danziger‐Isakov LA, delaMorena M, Hayashi RJ, et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung‐transplant recipients. Transplantation. 2003; 75:1538–1543.

Christie JD, Carby M, Bag R, et al.; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005; 24:1454–1459.

Christie JD, Kofloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Resp Crit Care Med. 2005; 171:1312–1316.

Shargall Y, Guenther G, Ahya VN, et al.; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant. 2005; 24:1489–1500.

Choong CK, Sweet SC, Zoole JB, et al. Bronchial airway anastomotic complications after pediatric lung transplantation: incidence, cause, management, and outcome. J Thorac Cardiovasc Surg. 2006; 131:198–203.

Ferdinande P, Bruyninckx F, Van Raemdonck D, Daenen W, Verleden G; Leuven Lung Transplant Group. Phrenic nerve dysfunction after heart‐lung and lung transplantation. J Heart Lung Transplant. 2004; 23:105–109.

Benden C, Aurora P, Curry J, et al. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol. 2005; 40:68–71.

Gandhi SK, Bromberg BI, Mallory GB, Huddleston CB. Atrial flutter: a newly recognized complication of pediatric lung transplantation. J Thorac Cardiovasc Surg. 1996; 112:992–1001.

Wong M, Mallory GB Jr, Goldstein J, Goyal M, Yamada KA. Neurologic complications of pediatric lung transplantation. Neurology. 1999; 53:1542–1549.

Verleden GM, Dupont LJ, Van Raemdonck DE. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J. 2005; 25:221–224.

Scott AI, Sharples LD, Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs. 2005; 65:761–771

Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007; 175:507–513.

Cantu E 3rd, Appel JZ 3rd, Hartwig MG, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004; 78:1142–1151.

Gottlieb J, Szangolies J, Koehnlein T, et al. Long‐term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008; 85:36–41.

Jaksch P, Scheed A, Keplinger M, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2012; 31:950–957.

Glanville AR. Antibody‐mediated rejection in lung transplantation: turning myth into reality. J Heart Lung Transplant. 2013; 32:12–13.

Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest. 2003; 124:1242–1249.

Gross TG, Orjuela MA, Perkins SL, et al. Low‐dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am J Transplant. 2012; 12:30693075.

Hayes D Jr, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty‐second pediatric lung and heart‐lung transplantation report—2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019; 38:1015–1027.

Barlow CW, Robbins RC, Moon MR, et al. Heart‐lung versus double‐lung transplantation for suppurative lung disease. J Thorac Cardiovasc Surg. 2000; 119:466–476.

Carvajal HG, Meritt TC, Pourney AN, Canter MW, Miller PJR. Pediatric Heart-Lung Transplantation Throug the Decades: A Single-Center Analysis. J Heart Lung Transplant. 2022; 41(4):S168.